Lenvatinib

CHEMBL1289601 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
426.9 g/mol
LogP
2.8
Phase
4

A multi-kinase inhibitor used to treat thyroid cancer, hepatocellular carcinoma, renal cell carcinoma, and endometrial cancer. It blocks multiple receptors involved in tumor blood vessel formation and cancer cell proliferation.

Berat Molekul

426,9000 g/mol

LogP

2,80

TPSA

116,00 Ų

Lipinski RO5

Lulus

Area Terapeutik

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O

InChI

InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)

Molecular Formula

C21H19ClN4O4

HBD / HBA

3 / 5

Ikatan yang Dapat Dirotasi

6

Atom Berat

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A multi-kinase inhibitor used to treat thyroid cancer, hepatocellular carcinoma, renal cell carcinoma, and endometrial cancer. It blocks multiple receptors involved in tumor blood vessel formation and cancer cell proliferation.

Yes, Lenvatinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1289601. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9823820. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.